Original Article| Volume 62, ISSUE 12, P1371-1379, December 15, 2007

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases

Published:September 10, 2007DOI:


      We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment.


      In this multicenter, double-blind study, outpatients with recurrent unipolar major depression were randomly assigned to receive venlafaxine ER (75–300 mg/day; n = 821) or fluoxetine (20–60 mg/day; n = 275). After a 10-week acute treatment phase, responders entered a 6-month continuation phase of ongoing therapy with double-blind venlafaxine ER (n = 530) or fluoxetine (n = 185). In the acute phase, the primary outcome was response, defined as a 17-item Hamilton Depression Rating Scale (HDRS) score ≤12 or ≥50% decrease from baseline; the secondary outcome was remission, defined as a HDRS score ≤7. In the continuation phase, the primary outcome was the proportion of patients who sustained response or remission. Secondary measures included time to onset of sustained response or remission (i.e., meeting criteria at two or more consecutive visits), relapse rates, and quality-of-life measures.


      At the acute treatment phase end point, response rates were 79% for both venlafaxine ER and fluoxetine; remission rates were 49% and 50% for venlafaxine ER and fluoxetine, respectively. In the continuation phase, response rates were 90% and 92%, and remission rates were 72% and 69% for venlafaxine ER and fluoxetine, respectively. Rates of sustained remission at the end of the continuation phase were 52% and 58% for venlafaxine ER and fluoxetine, respectively.


      Venlafaxine ER and fluoxetine were comparably effective during both acute and continuation phase therapy.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Keller M.B.
        • Lavori P.W.
        • Lewis C.E.
        • Klerman G.L.
        Predictors of relapse in major depressive disorder.
        JAMA. 1983; 250: 3299-3304
        • Solomon D.A.
        • Keller M.B.
        • Leon A.C.
        • Mueller T.I.
        • Lavori P.W.
        • Shea M.T.
        • et al.
        Multiple recurrences of major depressive disorder.
        Am J Psychiatry. 2000; 157: 229-233
        • Aberg-Wistedt A.
        • Agren H.
        • Ekselius L.
        • Bengtsson F.
        • Akerblad A.C.
        Sertraline versus paroxetine in major depression: Clinical outcome after six months of continuous therapy.
        J Clin Psychopharmacol. 2000; 20: 645-652
        • Montgomery S.A.
        • Rasmussen J.G.
        • Tanghoj P.
        A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.
        Int Clin Psychopharmacol. 1993; 8: 181-188
        • Montgomery S.A.
        • Reimitz P.E.
        • Zivkov M.
        Mirtazapine versus amitriptyline in the long-term treatment of depression: A double-blind placebo-controlled study.
        Int Clin Psychopharmacol. 1998; 13: 63-73
        • Simon J.S.
        • Aguiar L.M.
        • Kunz N.R.
        • Lei D.
        Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
        J Psychiatr Res. 2004; 38: 249-257
        • Lepine J.P.
        • Caillard V.
        • Bisserbe J.C.
        • Troy S.
        • Hotton J.M.
        • Boyer P.
        A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder.
        Am J Psychiatry. 2004; 161: 836-842
        • Gilaberte I.
        • Montejo A.L.
        • de la Gandara J.
        • Perez-Sola V.
        • Bernardo M.
        • Massana J.
        • et al.
        Fluoxetine in the prevention of depressive recurrences: A double-blind study.
        J Clin Psychopharmacol. 2001; 21: 417-424
        • Hochstrasser B.
        • Isaksen P.M.
        • Koponen H.
        • Lauritzen L.
        • Mahnert F.A.
        • Rouillon F.
        • et al.
        Prophylactic effect of citalopram in unipolar, recurrent depression: Placebo-controlled study of maintenance therapy.
        Br J Psychiatry. 2001; 178: 304-310
        • Montgomery S.A.
        • Entsuah R.
        • Hackett D.
        • Kunz N.R.
        • Rudolph R.L.
        Venlafaxine versus placebo in the preventive treatment of recurrent major depression.
        J Clin Psychiatry. 2004; 65: 328-336
        • Frank E.
        • Kupfer D.J.
        • Perel J.M.
        • Cornes C.
        • Jarrett D.B.
        • Mallinger A.G.
        • et al.
        Three-year outcomes for maintenance therapies in recurrent depression.
        Arch Gen Psychiatry. 1990; 47: 1093-1099
        • Judd L.L.
        • Akiskal H.S.
        • Maser J.D.
        • Zeller P.J.
        • Endicott J.
        • Coryell W.
        • et al.
        Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.
        J Affect Disord. 1998; 50: 97-108
        • Judd L.L.
        • Paulus M.J.
        • Schettler P.J.
        • Akiskal H.S.
        • Endicott J.
        • Leon A.C.
        • et al.
        Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?.
        Am J Psychiatry. 2000; 157: 1501-1504
        • Thase M.E.
        • Entsuah A.R.
        • Rudolph R.L.
        Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.
        Br J Psychiatry. 2001; 178: 234-241
        • Smith D.
        • Dempster C.
        • Glanville J.
        • Freemantle N.
        • Anderson I.
        Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis.
        Br J Psychiatry. 2002; 180: 396-404
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
        American Psychiatric Association, Washington, DC1994
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Rush A.J.
        • Giles D.E.
        • Schlesser M.A.
        • Fulton C.L.
        • Weissenburger J.
        • Burns C.
        The Inventory for Depressive Symptomatology (IDS): Preliminary findings.
        Psychiatry Res. 1986; 18: 65-87
        • Hamilton M.
        The assessment of anxiety states by rating.
        Br J Med Psychol. 1959; 32: 50-55
        • Guy W.
        Clinical global impressions.
        in: ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education and Welfare, National Institute of Mental Health, Bethesda, MD1976: 217-222
        • Weissman M.M.
        • Bothwell S.
        Assessment of social adjustment by patient self-report.
        Arch Gen Psychiatry. 1976; 33: 1111-1115
        • Keller M.B.
        • Lavori P.W.
        • Friedman B.
        • Nielsen E.
        • Endicott J.
        • McDonald-Scott P.
        • et al.
        The Longitudinal Interval Follow-up Evaluation.
        Arch Gen Psychiatry. 1987; 44: 540-548
        • Fawcett J.
        • Clark D.C.
        • Scheftner W.A.
        • Gibbons R.D.
        Assessing anhedonia in psychiatric patients.
        Arch Gen Psychiatry. 1983; 40: 79-84
        • Ware J.E.
        • Snow K.K.
        SF-36 Health Survey Manual and Information Guide.
        The Health Institute, New England Medical Center, Boston1993
        • Endicott J.
        • Nee J.
        • Harrison W.
        • Blumenthal R.
        Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure.
        Psychopharmacol Bull. 1993; 29: 321-326
        • Keller M.B.
        • Kocsis J.H.
        • Thase M.E.
        • Gelenberg A.J.
        • Rush A.J.
        • Koran L.
        • et al.
        Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial.
        JAMA. 1998; 280: 1665-1672
        • Bielski R.J.
        • Ventura D.
        • Chang C.C.
        A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
        J Clin Psychiatry. 2004; 65: 1190-1196
        • Detke M.J.
        • Lu Y.
        • Goldstein D.J.
        • Hayes J.R.
        • Demitrack M.A.
        Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial.
        J Clin Psychiatry. 2002; 63: 308-315
        • Rudolph R.L.
        • Feiger A.D.
        A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
        J Affect Disord. 1999; 56: 171-181
        • Silverstone P.H.
        • Ravindran A.
        Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety.
        J Clin Psychiatry. 1999; 60: 22-28
        • Suri R.A.
        • Altshuler L.L.
        • Rasgon N.L.
        • Calcagno J.L.
        • Frye M.A.
        • Gitlin M.J.
        • et al.
        Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder.
        J Clin Psychiatry. 2000; 61: 942-946
        • Trivedi M.H.
        • Pigotti T.A.
        • Perera P.
        • Dillingham K.E.
        • Carfagno M.L.
        • Pitts C.D.
        Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
        J Clin Psychiatry. 2004; 65: 1356-1364
        • Trivedi M.H.
        • Rush A.J.
        • Wisniewski S.R.
        • Nierenberg A.A.
        • Warden D.
        • Ritz L.
        • et al.
        Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice.
        Am J Psychiatry. 2006; 163: 28-40
        • Cipriani A.
        • Brambilla P.
        • Furukawa T.
        • Geddes J.
        • Gregis M.
        • Hotopf M.
        • et al.
        Fluoxetine versus other types of pharmacotherapy for depression.
        Cochrane Database Syst Rev. 2005; (CD004185)
      1. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Thase ME (submitted): Comprehensive analysis of remission (ComPARE) with venlafaxine vs SSRIs. Biol Psychiatry.

        • Edwards J.G.
        • Anderson I.
        Systematic review and guide to selection of selective serotonin reuptake inhibitors.
        Drugs. 1999; 57: 507-533
        • Heres S.
        • Davis J.
        • Maino K.
        • Jetzinger E.
        • Kissling W.
        • Leucht S.
        Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
        Am J Psychiatry. 2006; 163: 185-194
        • Thase M.E.
        Comparing the methods used to compare antidepressants.
        Psychopharmacol Bull. 2002; 36: 4-17

      Linked Article

      • Erratum
        Biological PsychiatryVol. 63Issue 7
        • Preview
          The financial and conflict of interest disclosures for two authors were inadvertently omitted from the article “The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases” by Keller et al., which appeared in the December 15, 2007 issue of Biological Psychiatry, Volume 62, Number 12 (Biol Psychiatry 2007;62:1371–1379). The missing disclosures are now listed here.
        • Full-Text
        • PDF
      • Erratum to: The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases
        Biological PsychiatryVol. 71Issue 4
        • Preview
          It has been discovered that the patient flowchart was not included in Supplement 2 for “The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases” by Keller et al., published in Biological Psychiatry (2007;62:1371–1379). The flowchart is referenced in the first sentence of the Results section, and is now printed here.
        • Full-Text
        • PDF